A α-1-Adrenergic receptor antagonist, antihypertensive.
Antihypertensive;Alpha1 agonist
Naftopidil dihydrochloride (10 mg/kg; p.o; daily; for 28 days) decreases microvessel density (MVD) in E9+PrSC tumors mice model[2].
| Animal Model: | Male athymic mice(7-8 weeks), with E9+PrSC xenograft[2] |
| Dosage: | 10 mg/kg |
| Administration: | Oral administration, daily, for 28 days |
| Result: | Decreased tumor weights. |
Alpha-1A adrenergic receptor: 3.7 nM (Ki); Alpha-1B adrenergic receptor: 20 nM (Ki); Alpha-1D adrenergic receptor: 1.2 (Ki)
